ProCE Banner Series

Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs

Join us in Chicago or online for a CME-certified satellite symposium featuring expert perspectives on the expanding role of next-generation therapeutics including oral SERDs in HR-positive/HER2-negative breast cancer. Throughout the session, experts will answer audience questions in a live question and answer sessions. Register now!

Not an official event of the 2024 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.

Who Should Attend

This program is intended for medical oncologists and other healthcare professionals who treat patients with breast cancer.

All Events

Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs

Past Events




6:30 PM - 8:30 PM Central Time (CT)


Hilton Chicago, 720 S Michigan Ave, Chicago, Illinois 60605

7:00 PM - 8:30 PM Central Time (CT)



ProCE Banner Faculty
Aditya Bardia, MD, MPH, FASCO

Professor of Medicine
Geffen School of Medicine at UCLA
Director, Breast Oncology Program
Assistant Chief (Translational Research)
Division of Medical Oncology
Director of Translational Research Integration
UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, California

ProCE Banner Faculty
Virginia Kaklamani, MD, DSc

Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
A.B. Alexander Distinguished Chair in Oncology
Breast Oncology Program
UT Health San Antonio
MD Anderson Cancer Center
San Antonio, Texas

ProCE Banner Faculty
Sarah Sammons, MD

Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts


Steps Toward Precision Oncology: Attacking Endocrine Resistance in HR-Positive/HER2-Negative Breast Cancer

  • Panel Discussion: Clinical Strategies for Addressing Endocrine Resistance

The Expanding Evidence Base for Oral SERDs and Other ER-Targeting Agents

  • Panel Discussion: Clinical Considerations and Conundrums

A Peek at the Crystal Ball: Possibilities for the Future for HR-Positive/HER2-Negative Breast Cancer

  • Panel Discussion: The Potential Impact of Emerging Data on Clinical Practice

Audience Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.


Goal Statement
The goal of this program is to improve the knowledge, confidence, and competence of learners to integrate available clinical data on oral SERDs into practice for patients with hormone receptor–positive, HER2-negative breast cancer.

Target Audience
This program is intended for medical oncologists and other healthcare professionals who treat patients with breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Plan individualized treatment with oral SERDs for patients with HR+/HER2- mBC progressing on first-line endocrine therapy based on individual patient and disease characteristics, genomic profile, available clinical data, current guidelines, and expert recommendations

  • Effectively mitigate and manage toxicities associated with oral SERD therapy for patients with HR+/HER2- breast cancer

  • Implement recommended strategies to improve adherence to and persistence with oral SERD therapy in patients with HR+/HER2- breast cancer

  • Identify patients with HR+/HER2- breast cancer who may be eligible for enrollment on a clinical trial investigating oral SERDs or other precision medicine approaches


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification 

Successful completion of this CME activity, which included participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

CME Passport 


The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit to create your account. 

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


Provided by Clinical Care Options, LLC

Supported by educational grants from AstraZeneca and Lilly.